



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Biofeedback as a Treatment of Fecal Incontinence or Constipation

Table of Contents

- [Policy: Commercial](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Policy: Medicare](#)
- [Description](#)
- [References](#)
- [Authorization Information](#)
- [Policy History](#)

Policy Number: 308

BCBSA Reference Number: 2.01.64

NCD/LCD: National Coverage Determination (NCD) for BIOFEEDBACK Therapy (30.1)

Related Policies

- Biofeedback as a Treatment of Chronic Pain, #[210](#)
- Sacral Nerve Neuromodulation/Stimulation for Pelvic Floor Dysfunction, #[153](#)
- Biofeedback as a Treatment of Urinary Incontinence, #[173](#)
- Transanal Radiofrequency Treatment of Fecal Incontinence #[309](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Biofeedback for constipation in adults may be **MEDICALLY NECESSARY** for patients with dyssynergia-type constipation as demonstrated by meeting all 3 of the following criteria:

1. Symptoms of functional constipation that meet ROME III criteria
2. Objective physiologic evidence of pelvic floor dyssynergia demonstrated by inappropriate contraction of the pelvic floor muscles or less than 20% relaxation of basal resting sphincter pressure by manometry, imaging or EMG;
3. Failed a 3-month trial of standard treatments for constipation including laxatives, dietary changes, and exercises (as many of the previous as are tolerated).

Note: Rome III diagnostic criteria for functional constipation*

1. Must include two or more of the following:
 - a. Straining during at least 25% of defecations
 - b. Lumpy or hard stools in at least 25% of defecations
 - c. Sensation of incomplete evacuation for at least 25% of defecations
 - d. Sensation of anorectal obstruction/blockage for at least 25% of defecations
 - e. Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
 - f. Fewer than three defecations per week
2. Loose stools are rarely present without the use of laxatives
3. Insufficient criteria for irritable bowel syndrome

* Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

Rome III diagnostic criterion for dyssynergic defecation:

Inappropriate contraction of the pelvic floor or less than 20% relaxation of basal resting sphincter pressure with adequate propulsive forces during attempted defecation

Guidance on Biofeedback Protocol

The recommended treatment course for patients with constipation who meet criteria is up to 6 biofeedback sessions over 3 months.

Biofeedback is considered [INVESTIGATIONAL](#) as a treatment of constipation in adults and children in all other situations

Biofeedback is considered [INVESTIGATIONAL](#) as a treatment of fecal incontinence in adults and children.

Medicare HMO BlueSM and Medicare PPO BlueSM Members

BCBSMA covers biofeedback as a treatment of fecal incontinence and constipation for the following indications for Medicare HMO Blue and Medicare PPO Blue members in accordance with CMS NCD:

- When it is reasonable and necessary for the individual patient for muscle re-education of specific muscle groups, or
- For treating pathological muscle abnormalities of spasticity, incapacitating muscle spasm; or weakness, and more conventional treatments (heat, cold, massage, exercise, support) have not been successful.

BCBSMA does not cover biofeedback as a treatment of fecal incontinence for the following indication for Medicare HMO Blue and Medicare PPO Blue members in accordance with CMS NCD:

- The treatment of ordinary muscle tension states or for psychosomatic conditions.

Medical necessity criteria and coding guidance can be found through the link below.

[National Coverage Determinations \(NCDs\)](#)

National Coverage Determination (NCD) for BIOFEEDBACK Therapy (30.1)

Note: To review the specific NCD, please remember to click “accept” on the CMS licensing agreement at the bottom of the CMS webpage.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .
Medicare HMO Blue SM	Prior authorization is not required .
Medicare PPO Blue SM	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

CPT Codes

CPT codes:	Code Description
90875	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); approximately 20-30 minutes
90876	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); approximately 45-50 minutes
90901	Biofeedback training by any modality
90911	Biofeedback training, perineal muscles, anorectal, or urethral sphincter, including EMG and/or manometry

ICD-10 Diagnosis Codes

ICD-10-CM Diagnosis codes:	Code Description
K59.02	Outlet dysfunction constipation
R15.0	Incomplete defecation

ICD-10 Procedure Codes

ICD-10-PCS procedure codes:	Code Description
GZC9ZZZ	Biofeedback

Description

FECAL INCONTINENCE AND CONSTIPATION

Adults

Fecal incontinence in adults is the recurrent uncontrolled passage of fecal material. Pathophysiology of the disorder ranges from abnormalities in intestinal motility (diarrhea or constipation) to poor rectal compliance, impaired rectal sensation, or weak or damaged pelvic floor muscles. There is no increase in mortality attributable to fecal incontinence. Morbidity includes skin breakdown and urinary tract infections. Fecal incontinence may affect the quality of life by restricting work, recreation, and activities related to “getting out of the house,” impaired social role function, diminished sexual activity, and increase of social isolation due to embarrassment. Fecal incontinence can bring about the loss of independence and mobility. It is the second most common reason for elderly institutionalization. The most common causes of fecal incontinence in adults are obstetric trauma coupled with age-related degeneration, previous anorectal surgery, rectal prolapse, and perineal trauma. In many individuals, the condition is multifactorial, involving a combination of structural, physiological, and psychosocial factors. Conventional interventions to treat fecal incontinence include dietary recommendations (eg, fiber), bowel and toilet scheduling, and medications (eg, bulking or antidiarrheal agents).

Constipation refers to infrequent bowel movements and difficulty expelling stool during defecation. Primary constipation is categorized into 3 groups. The most common type is normal-transit constipation in which there is a normal rate of stool movement, but patients feel constipated and may complain of abdominal pain and/or bloating. In the second type, slow-transit constipation, stool moves more slowly through the colon and individuals often experience a limited urge to defecate. The third type, dyssynergic defecation, refers to a loss of ability to coordinate contractions of the pelvic floor muscles and to relax the anal sphincter during defecation. Patients often report an inability to defecate despite the urge to do so. There are also secondary causes of constipation such as the use of certain medications, including opioids and psychoactive drugs; neurologic, endocrine, or metabolic disorders; structural abnormalities; and lifestyle factors. Conventional treatment includes dietary changes (ie, adequate fiber and fluid intake), use of supplemental bulking substances, exercises, and medications.

Children

In children, most cases of fecal incontinence and constipation are functional, in which structural, endocrine, or metabolic diseases have been ruled out. Factors contributing to functional incontinence and constipation are fear and/or pain associated with large, hard stools. This leads to retentive posturing in approximately half the children with chronic constipation (ie, the avoidance of defecation by purposefully contracting the external anal sphincter, also termed anismus or paradoxical sphincter contraction). Customary or conventional medical intervention includes dietary changes, bowel and toilet scheduling, softening agents, and education. Behavioral interventions aim to restore normal bowel habits through toilet training, reward and incentive contingency management programs, desensitization of phobia and fear, or skill-building and goal-setting techniques with home practice. Counseling and psychotherapy provide support to the child and address social and psychological problems.

BIOFEEDBACK

Biofeedback, a technique intended to teach patients self-regulation of certain physiologic processes not normally considered to be under voluntary control, is used for various conditions and is proposed as a treatment of fecal incontinence and constipation.

Biofeedback training for fecal incontinence focuses on improving the ability to voluntarily contract the external anal sphincter and puborectalis muscles in response to rectal filling and to decrease delay in response to a sensation of distension. For constipation, biofeedback aims to teach patients how to tighten and relax their external anal sphincter to pass bowel movements.

Biofeedback attempts to improve rectal sensory perception, strength, coordination, or some combination of these 3 components. Sensory training involves inducing intrarectal pressure using a balloon feedback device. A manometric balloon probe is inserted into the rectum, and the balloon is filled with air to produce a sensation of rectal filling. Strength training uses either anal canal pressure (manometric) or intra-anal electromyography feedback of pelvic floor muscles. The purpose is to strengthen the force of the pelvic floor muscles contraction without including rectal distention. Some training increases endurance (duration of external anal sphincter contraction) as well as peak strength. Coordination training uses pressure feedback of intrarectal balloon distention with a water-perfused catheter or Schuster-type balloon probe and pelvic floor muscles contractions in a simultaneous feedback display. The purpose of coordination training is to synchronize the contraction of the external anal sphincter with the relaxation of the internal anal sphincter.

Biofeedback techniques convert the physiologic measures from an intra-anal electromyography sensor, anal manometric probe (measuring intra-anal pressure), or perianal surface electromyography electrodes to either a visual or audio display for feedback. Ultrasound has also been used to show patients' contraction of the anal sphincter on a screen. Biofeedback training is done alone or in combination with other behavioral therapies designed to teach relaxation. Training sessions are performed in a quiet, nonarousing environment.

Summary

Biofeedback is a technique to teach patients self-regulation of physiological processes not generally considered to be under voluntary control; a variety of approaches and devices are available. Among possible indications, biofeedback is proposed as a treatment for fecal incontinence and constipation.

For individuals who have fecal incontinence who receive biofeedback, the evidence includes randomized controlled trials (RCTs) and systematic reviews. The relevant outcomes are symptoms, functional outcomes, and quality of life. One RCT reported a significantly greater decrease in fecal incontinence symptoms with biofeedback plus exercise training compared with exercise training alone, however, most trials have not shown a significant benefit. Systematic reviews have not found that biofeedback plus conventional therapy provides additional benefit compared with conventional therapy alone. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have constipation other than dyssynergia-type constipation who receive biofeedback, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional

outcomes, and quality of life. A systematic review of RCTs found a benefit of biofeedback as a treatment for constipation in adults. Conclusions of the systematic review were limited by variability in patient populations (which combined both dyssynergia-type and non-dyssynergia-type), comparator groups, and outcome measures, and biofeedback was not clearly beneficial for nondyssynergia types of constipation. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have dyssynergia-type constipation who receive biofeedback, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, and quality of life. Several well-conducted RCTs focusing on patients with dyssynergia-type constipation have reported benefits in a subgroup of patients meeting well-defined criteria. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy History

Date	Action
1/2019	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
12/2016	New references added from BCBSA National medical policy.
1/2016	New references added from BCBSA National medical policy.
3/2015	New references added from BCBSA National medical policy.
5/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.
4/2014	New references added from BCBSA National medical policy.
1/2014	Coding information clarified.
7/2013	BCBSA National medical policy review. New medically necessary indications described; investigational statement on constipation modified. Effective 7/1/2013.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
10/2011	Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements.
1/21/2011	New policy, effective 1/21/2011, describing covered and non-covered indications.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Food and Drug Administration. Biofeedback device. 21 CFR § 882.5050 (1998).
2. Vonthein R, Heimerl T, Schwandner T, et al. Electrical stimulation and biofeedback for the treatment of fecal incontinence: a systematic review. *Int J Colorectal Dis*. Nov 2013;28(11):1567-1577. PMID 23900652
3. Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. *Cochrane Database Syst Rev*. Jul 11 2012;7(7):CD002111. PMID 22786479
4. Enck P, Van der Voort IR, Klosterhalfen S. Biofeedback therapy in fecal incontinence and constipation. *Neurogastroenterol Motil*. Nov 2009;21(11):1133-1141. PMID 19566591
5. Bartlett L, Sloots K, Nowak M, et al. Biofeedback for fecal incontinence: a randomized study comparing exercise regimens. *Dis Colon Rectum*. Jul 2011;54(7):846-856. PMID 21654252

6. Heymen S, Scarlett Y, Jones K, et al. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. *Dis Colon Rectum*. Oct 2009;52(10):1730-1737. PMID 19966605
7. Norton C, Chelvanayagam S, Wilson-Barnett J, et al. Randomized controlled trial of biofeedback for fecal incontinence. *Gastroenterology*. Nov 2003;125(5):1320-1329. PMID 14598248
8. Solomon MJ, Pager CK, Rex J, et al. Randomized, controlled trial of biofeedback with anal manometry, transanal ultrasound, or pelvic floor retraining with digital guidance alone in the treatment of mild to moderate fecal incontinence. *Dis Colon Rectum*. Jun 2003;46(6):703-710. PMID 12794569
9. Brazzelli M, Griffiths PV, Cody JD, et al. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. *Cochrane Database Syst Rev*. Dec 07 2011(12):CD002240. PMID 22161370
10. Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. *Cochrane Database Syst Rev*. Mar 26 2014;3(3):CD008486. PMID 24668156
11. van Ginkel R, Buller HA, Boeckxstaens GE, et al. The effect of anorectal manometry on the outcome of treatment in severe childhood constipation: a randomized, controlled trial. *Pediatrics*. Jul 2001;108(1):E9. PMID 11433088
12. Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. *Dis Colon Rectum*. Apr 2007;50(4):428-441. PMID 17294322
13. Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. *Clin Gastroenterol Hepatol*. Mar 2007;5(3):331-338. PMID 17368232
14. Rao SS, Valestin J, Brown CK, et al. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. *Am J Gastroenterol*. Apr 2010;105(4):890-896. PMID 20179692
15. Rao SS, Benninga MA, Bharucha AE, et al. ANMS-ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders. *Neurogastroenterol Motil*. May 2015;27(5):594-609. PMID 25828100
16. Paquette IM, Varma MG, Kaiser AM, et al. The American Society of Colon and Rectal Surgeons' clinical practice guideline for the treatment of fecal incontinence. *Dis Colon Rectum*. Jul 2015;58(7):623-636. PMID 26200676
17. Paquette IM, Varma M, Ternent C, et al. The American Society of Colon and Rectal Surgeons' clinical practice guideline for the evaluation and management of constipation. *Dis Colon Rectum*. Jun 2016;59(6):479-492. PMID 27145304
18. American Gastroenterological Association, Bharucha AE, Dorn SD, et al. American Gastroenterological Association medical position statement on constipation. *Gastroenterology*. Jan 2013;144(1):211-217. PMID 23261064
19. Bharucha AE, Rao SSC, Shin AS. Surgical interventions and the use of device-aided therapy for the treatment of fecal incontinence and defecatory disorders. *Clin Gastroenterol Hepatol*. Dec 2017;15(12):1844-1854. PMID 28838787
20. National Institute for Health and Care Excellence (NICE). Constipation in children and young people: diagnosis and management [CG99]. 2017; <https://www.nice.org.uk/guidance/cg99>. Accessed September 17, 2018.
21. National Institute for Health and Care Excellence (NICE). Faecal incontinence in adults: management [CG49]. 2007; <https://www.nice.org.uk/guidance/cg49>. Accessed September 17, 2018.
22. Wald A, Bharucha AE, Cosman BC, et al. ACG clinical guideline: management of benign anorectal disorders. *Am J Gastroenterol*. Aug 2014;109(8):1141-1157; (Quiz) 1058. PMID 25022811
23. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Biofeedback Therapy (30.1). n.d.; https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?TAId=10&MEDCACId=15&CALId=185&MCDId=27&NCDId=41&ncdver=1&CoverageSelection=National&ncd_id=20.20&ncd_version=2&basket=ncd%2525253A20%2525252E20%2525253A2%2525253AExternal+Counterpulsation+%25252528ECP%25252529+for+Severe+Angin&bc=gAAABAAAAAAA%3D%3D&. Accessed September 17, 2018.